STAT

MAY 19, 2024

Removing a patient’s race from an equation used to assess lung function — a change called for by health equity advocates — would mean that the lung disease of nearly half a million Black Americans would be reclassified as being more severe, and that Black veterans could receive more than $1 billion in additional disability payments, according to a study published Sunday in the New England Journal of Medicine.

139

139

Pharmacy Times

MAY 19, 2024

Researchers observed that patients aged 80 years and older with acute myeloid leukemia who were treated with venetoclax and a hypomethylating agent had prolonged overall survival.

123

123

Drug Topics

MAY 19, 2024

In case you missed it, this week we had news about joint business ventures in pharmacy, an uptick in fentanyl seizures across the US, sunscreen safety, and more.

98

98

The FDA Law Blog

MAY 19, 2024

By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C. aimed at identifying and characterizing the challenges in developing therapies for ultra-rare diseases and conditions that affect exceedingly small populations. The workshop will drive in-depth discussions from leaders across federal agencies, the patient advocacy community, industry, academia and policy to examine the current state of

FDA 59

FDA 59

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

MAY 19, 2024

Discover what industry professionals seek in contract manufacturing for parenteral solutions. Ensure quality, compliance, and innovation with our comprehensive guide. Click to learn more.

52

52

Med Ed 101

MAY 19, 2024

Thiazide diuretics are commonly are one of the most commonly used classes of antihypertensive agents. They carry many adverse effects. Some can be a nuisance while others can be more serious. In this blog post, I’ll run down the most common thiazide diuretic adverse effects to be aware of. Urinary Frequency I would classify urinary […] The post Top 5 Thiazide Diuretic Adverse Effects appeared first on Med Ed 101.

52

52

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.

52

52

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

52

52

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Biliary Tract Cancer.

52

52

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Pancreatic Cancer.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Renal Cell Carcinoma.

52

52

Pharmaceutical Technology

MAY 19, 2024

Olverembatinib is under clinical development by Ascentage Pharma Group International and currently in Phase II for Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia).

40

40

Pharmaceutical Technology

MAY 19, 2024

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma).

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.

40

40

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Pharmaceutical Technology

MAY 19, 2024

Furmonertinib mesylate is under clinical development by Shanghai Allist Pharmaceuticals and currently in Phase II for Lung Adenocarcinoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Elixcyte is under clinical development by Unicocell Biomed and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure).

40

40

Pharmaceutical Technology

MAY 19, 2024

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Neuroblastoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Afamitresgene autoleucel is under clinical development by Adaptimmune Therapeutics and currently in Phase II for Osteosarcoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Biliary Tract Cancer.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Metastatic Pancreatic Cancer.

40

40

Pharmaceutical Technology

MAY 19, 2024

Vusolimogene oderparepvec is under clinical development by Replimune and currently in Phase II for Metastatic Melanoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Malignant Mesothelioma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Renal Cell Carcinoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

Dipraglurant is under clinical development by Addex Therapeutics and currently in Phase II for Blepharospasm.

40

40

Pharmaceutical Technology

MAY 19, 2024

Rucaparib camsylate is under clinical development by pharmaand and currently in Phase II for Cervical Cancer.

40

40

Pharmaceutical Technology

MAY 19, 2024

PLX-038 is under clinical development by ProLynx and currently in Phase II for Recurrent Medulloblastoma.

40

40

Pharmaceutical Technology

MAY 19, 2024

SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers.

40

40

Pharmaceutical Technology

MAY 19, 2024

PLX-038 is under clinical development by ProLynx and currently in Phase II for Ependymoma.

40

40